Literature DB >> 9597153

Cannabinoid receptors and their endogenous agonists.

C C Felder1, M Glass.   

Abstract

Marijuana has been in use for over 4000 years as a therapeutic and as a recreational drug. Within the past decade, two cannabinoid receptor types have been identified, their signal transduction characterized, and an endogenous lipid agonist isolated from mammalian tissues. The CB1 cannabinoid receptor is widely distributed in mammalian tissues, with the highest concentrations found in brain neurons. CB1 receptors are coupled to modulation of adenylate cyclase and ion channels. The CB2 receptor is found in cells of the immune system and is coupled to inhibition of adenylate cyclase. Both receptor types selectively bind delta 9-THC, the active principle in marijuana, and anandamide (arachidonylethanolamide), an endogenous cannabimimetic eicosanoid. Progress is being made in the development of novel agonists and antagonists with receptor subtype selectivity, mice with genetic deletion of the cannabinoid receptors, and receptor-specific antibodies, which should help in providing a better understanding of the physiological role of the cannabinoid receptors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9597153     DOI: 10.1146/annurev.pharmtox.38.1.179

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  66 in total

1.  Functional interaction between opioid and cannabinoid receptors in drug self-administration.

Authors:  M Navarro; M R Carrera; W Fratta; O Valverde; G Cossu; L Fattore; J A Chowen; R Gomez; I del Arco; M A Villanua; R Maldonado; G F Koob; F Rodriguez de Fonseca
Journal:  J Neurosci       Date:  2001-07-15       Impact factor: 6.167

Review 2.  Cannabinoid neuroimmune modulation of SIV disease.

Authors:  Patricia E Molina; Angela Amedee; Nicole J LeCapitaine; Jovanny Zabaleta; Mahesh Mohan; Peter Winsauer; Curtis Vande Stouwe
Journal:  J Neuroimmune Pharmacol       Date:  2011-08-10       Impact factor: 4.147

3.  High times for cannabis research.

Authors:  L Iversen
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

4.  CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: potential role for CB2-selective ligands as immunosuppressive agents.

Authors:  Catherine Lombard; Mitzi Nagarkatti; Prakash Nagarkatti
Journal:  Clin Immunol       Date:  2006-12-20       Impact factor: 3.969

5.  Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes.

Authors:  Régis Roche; Laurence Hoareau; Sandrine Bes-Houtmann; Marie-Paule Gonthier; Christine Laborde; Jean-François Baron; Yacine Haffaf; Maya Cesari; Franck Festy
Journal:  Histochem Cell Biol       Date:  2006-01-04       Impact factor: 4.304

Review 6.  Marijuana dependence: not just smoke and mirrors.

Authors:  Divya Ramesh; Joel E Schlosburg; Jason M Wiebelhaus; Aron H Lichtman
Journal:  ILAR J       Date:  2011

7.  Cannabinoids as anticancer therapeutic agents.

Authors:  Olga Kovalchuk; Igor Kovalchuk
Journal:  Cell Cycle       Date:  2020-04-05       Impact factor: 4.534

8.  Differential alteration of hippocampal excitatory synaptic transmission by cannabinoid ligands.

Authors:  Michal Bajo; Marisa Roberto; Paul Schweitzer
Journal:  J Neurosci Res       Date:  2009-02-15       Impact factor: 4.164

Review 9.  Role of endocannabinoid system in mental diseases.

Authors:  Jorge Manzanares; Leyre Urigüen; Gabriel Rubio; Tomás Palomo
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

10.  Electrophysiological effects of anandamide on rat myocardium.

Authors:  Qian Li; Hui-Jie Ma; Hao Zhang; Zhao Qi; Yue Guan; Yi Zhang
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.